Search
Tropisetron
go.drugbank.com/drugs/DB11699ApprovedInvestigationalWithdrawnTropisetron is an indole derivative with antiemetic activity. As a selective serotonin receptor antagonist, tropisetron competitively blocks the action of serotonin at 5HT3 receptors, resulting in suppression of chemotherapy- and radioth...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesLinerixibat
go.drugbank.com/drugs/DB11729ApprovedInvestigationalLinerixibat is a first-in-class and small-molecule inhibitor of the ileal bile acid transporter (IBAT). On March 19, 2026, linerixibat was approved by the FDA for the treatment of cholestatic pruritus in patients with primary biliary cho...
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsLasmiditan
go.drugbank.com/drugs/DB11732ApprovedInvestigationalLasmiditan is an oral medication used in the termination of migraine headaches that was first approved for use in the United States in October 2019. It was also approved by the European Commission on August 17, 2022. Traditionally, the t...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesRifamycin
go.drugbank.com/drugs/DB11753ApprovedInvestigationalWithdrawnRifamycin is the prime member of the rifamycin family which are represented by drugs that are a product of fermentation from the gram-positive bacterium Amycolatopsis mediterranei, also known as Streptomyces mediterranei. The parent comp...
Categories: Cytochrome P-450 CYP2B6 Inducers, P-glycoprotein inhibitorsDanoprevir
go.drugbank.com/drugs/DB11779InvestigationalDanoprevir has been used in trials studying the treatment of Hepatitis C, Chronic.
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsFostemsavir
go.drugbank.com/drugs/DB11796ApprovedInvestigationalFostemsavir is the phosphonooxymethyl prodrug of temsavir, a novel HIV-1 attachment inhibitor. It binds to and inhibits the activity of gp120, a subunit within the HIV-1 gp160 envelope glycoprotein that facilitates the attachment of HIV-...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesEsketamine
go.drugbank.com/drugs/DB11823ApprovedInvestigationalMajor depressive disorder (MDD) is a significant cause of disability worldwide and the most common illness preceding suicide. On March 5, 2019, the nasal spray drug, esketamine, also known as Spravato (by Janssen Pharmaceuticals), was ap...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 InducersInfigratinib
go.drugbank.com/drugs/DB11886ApprovedInvestigationalWithdrawnInfigratinib is a pan-fibroblast growth factor receptor (FGFR) kinase inhibitor. By inhibiting the FGFR pathway, which is often aberrated in cancers such as cholangiocarcinoma, infigratinib suppresses tumour growth. Cholangiocarcinoma is...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsValbenazine
go.drugbank.com/drugs/DB11915ApprovedInvestigationalValbenazine is a modified metabolite of tetrabenazine, and it is currently being approved for the treatment of various movement disorders, particularly tardive dyskinesia and chorea associated with Huntington's disease. Tardive dyskinesi...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesElagolix
go.drugbank.com/drugs/DB11979ApprovedInvestigationalElagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Adm...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors